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Abstract—Systemic lupus erythematosus (SLE) is a systemic autoimmune disease resulting in loss of
self-tolerance with multiple organs, such as the kidney, skin, joints, and the central nervous system
(CNS), being targeted. Numerous immunosuppressant therapies are currently being used for the
treatment of SLE, but their clinical utility is somewhat variable because of the clinical heterogeneity.
Melanocortins are a family of peptides derived from the common precursor protein pro-
opiomelanocortin. These multifunctional peptides activate five subtypes of melanocortin receptors
expressed on immune, skin, muscle, bone, and kidney cells and cells within the CNS. Melanocortin
peptides have demonstrated a variety of biologic actions including immunomodulation, melanogenesis,
and renoprotection. This review aims to introduce the melanocortin system and explore the mechanisms
by which they may be beneficial in diseases such as SLE.
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INTRODUCTION
Systemic Lupus Erythematosus (SLE) is character-
ized by the loss of self-tolerance and chronic inflammation
that manifest in organs such as the skin, kidney, and central
nervous system (CNS). High levels of morbidity and mor-
tality are associated with SLE, resulting from damage in a
variety of organs. A hallmark of SLE is the presence of
autoantibodies, which can be directed against nuclear and
cytoplasmic antigens. These observations have led to a
strong interest in therapeutically targeting the immune
system. A number of immunosuppressant therapies are
currently used for the treatment of SLE, including synthetic
glucocorticoids, anti-malarials, and other immune suppres-
sants, including the B cell-targeted therapy Benlysta®
(belimumab) [1]. Belimumab is a human monoclonal an-
tibody that inhibits B cell activating factor (BAFF, a B cell
survival factor), which subsequently reduces immature B
cell populations and serum autoantibody levels [2]. Since
the immune complex deposition within end organs is the
key contributor to end organ damage, targeting B cell
populations is an ideal strategy. Other potential new ther-
apies are designed to target immune cell function known to
be important in the pathogenesis of SLE, including target-
ing B cell survival, various lymphocyte receptors, and
inhibiting interferon alpha (IFN-α).
The immune hyperactivity of SLE can be inferred
systemically by elevations in levels of cytokines and upre-
gulation of their associated receptors [3]. For example,
interleukin (IL)-17 is a cytokine that induces the produc-
tion of inflammatory and tissue-damaging molecules [4].
Serum or plasma levels of IL-17, as well as expansion of
IL-17-producing T cells in the peripheral blood, are both
elevated in patients with SLE [4]. The commitment of
naïve T lymphocytes (CD4+) to the Th17 lineage is
attributed to, among other mechanisms, the presence of
both transforming growth factor (TGF)-β and IL-6 [4].
The concentration of TGF-β1 also was found to be de-
creased in SLE patients compared to healthy controls [5].
Three of the 11 ACR criteria for SLE relate to photo-
distribution and skin manifestations [6], and skin manifes-
tations are the most frequently observed symptom in SLE
patients. The underlying pathogenesis of cutaneous SLE is
thought to involve antibody deposition at the dermal-
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epidermal junction, keratinocyte hyperproliferation with
early differentiation, and premature terminal differentiation
and inflammatory cell infiltrates [6]. Photosensitivity is one
of the major manifestations of SLE, and cutaneous lupus
lesions can be triggered by sunlight exposure possibly from
induction of UV-induced apoptosis. The mean number of
p53-positive (apoptosis marker) keratinocytes in the skin
of SLE patients with cutaneous manifestations is signifi-
cantly higher than that of SLE patients with no cutaneous
manifestations or healthy volunteers [7].
Beyond circulating immune cell changes and inflam-
matory mediators upregulated in the periphery, immune
complex deposition occurs in several organ systems, result-
ing in inflammation and organ damage. The key organs
include the kidneys, brain, and skin. Lupus nephritis is one
of the most severe manifestations of SLE and is associated
with considerable morbidity and mortality. Up to 35 % of
patients with SLE present with signs of lupus nephritis at
the time of diagnosis, and up to 60 % of patients develop
lupus nephritis within the first 10 years of their disease.
The presence of lupus nephritis significantly decreases the
chance of 10-year survival [8]. The development of ne-
phritic lesions in SLE patients is likely from a combination
of increased inflammatory activity, B cell and T cell dys-
function, aggregate antibody complex formation, and sub-
sequent complement activation [9].
CNS lupus is area of high unmet need, as many
current treatment options and studies exclude CNS lupus.
Clinical manifestations of CNS lupus are broad, ranging
from psychosis and stroke to subclinical cognitive dysfunc-
tion [10]. The pathogenesis of CNS lupus is poorly under-
stood, although anti-phospholipid antibodies, vasculop-
athy and vasculitis, and local inflammatory processes have
been implicated. Additionally, intrathecal levels of glial
fibrillary acidic protein (GFAP) were increased in SLE
patients with CNS involvement compared to SLE without
overt CNS disease. GFAP is an intermediate filament pro-
tein expressed by astrocytes, and cerebrospinal fluid levels
of GFAP in SLE patients are significantly correlated with
MRI abnormalities [11]. Therefore, damage to glial cells
within the brain may contribute to the pathogenesis of CNS
lupus.
The immune processes and organs affected by SLE
may be viable therapeutic targets of steroid-dependent and
steroid-independent effects of adrenocorticotropin hor-
mone (ACTH). ACTH was approved in the early 1950s
and was used interchangeably with prednisone for numer-
ous inflammatory diseases, including rheumatoid arthritis
and SLE. ACTH is well known to stimulate endogenous
cortisol production and is a key component of the
hypothalamic-pituitary adrenal axis. However, ACTH also
has activity at melanocortin receptors outside of the adrenal
gland where biologic activity extends beyond steroidogen-
esis. Melanocortins are endogenously produced and have
demonstrated anti-inflammatory and organ-protective
effects [12–14]. This review aims to provide a broader
appreciation of the melanocortin peptides, highlight their
anti-inflammatory effects on varied immune cell subsets,
and stimulate discussion on the possible role(s) for mela-
nocortins in the treatment of SLE.
MELANOCORTIN PEPTIDES AND RECEPTORS
The melanocortin peptides include ACTH, alpha-
melanocyte-stimulating hormone (α-MSH), β-MSH, and
γ-MSH, all of which are cleaved from a common precursor
polypeptide, pro-opiomelanocortin (POMC, see Fig. 1
[15]) [16]. POMC is predominantly synthesized and pro-
cessed in the pituitary gland, although small amounts of
this precursor protein are also synthesized and processed in
extrapituitary sites, including immune and skin cells [17].
POMC is proteolytically cleaved into numerous fragments,
including ACTH. ACTH is a 39-amino acid peptide that
can be further cleaved to generate α-MSH, which is the
first 13 amino acids of ACTH [17]. All melanocortin
peptides, ACTH, α-MSH, β-MSH, and γ-MSH, have a
core sequence of four amino acids (His-Phe-Arg-Trp) that
are required for receptor binding [18]. Synthetic melano-
cortin peptides have been developed, including ACTH (1–
24) also named tetracosactide. Of the synthetic agents,
tetracosactide is used clinically outside of the USA for
diseases other than lupus, while the other synthetic mela-
nocortin analogues are being tested in preclinical models or
in early phase development.
Melanocortin peptides bind with different affinities
and selectivity to five identified melanocortin receptor
subtypes (melanocortin receptors (MC1–5R) that are dis-
tributed onmultiple cell populations distributed throughout
the body [19]. The MC1R has a well-characterized in-
volvement in skin and hair pigmentation and immune cell
regulation [20], while ACTH is the only melanocortin
peptide that activates MC2Rs in the adrenal gland to stim-
ulate glucocorticoid synthesis and release [21]. MC3R
regulates immune cell function, and both MC3R and
MC4R have roles in energy homeostasis and regulate
neuronal interactions with autonomic functions [22–24].
The MC5R is expressed on a broad range of tissues
throughout the body; however, its function remains to be
fully elucidated, although this receptor has been implicated
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in sebaceous gland function and in the stress response,
based on its primary expression in exocrine glands [25].
Melanocortin receptors are transmembrane, G
protein-coupled receptors (GPCRs) that regulate diverse
intracellular signal transduction mechanisms, including
cyclic adenosine monophosphate (cAMP) and protein ki-
nase A (PKA) signaling pathways [26, 27]. One of the
downstream effects of the melanocortin intracellular cas-
cade is inhibition of the canonical pro-inflammatory tran-
scription factor nuclear factor kappa B (NF-κB). This
effect of melanocortin receptor activation appears to be
dose and time dependent and involves stabilization of the
cytosolic inhibitory IκB protein, which retains NF-κB
within the cytoplasm, thereby preventing NF-κB from
translocating to the nucleus and driving pro-inflammatory
mediator transcription [28, 29]. Other intracellular cas-
cades can be activated by melanocortin receptor signaling,
for example, ERK1/2 signaling, Jak/STAT signaling, and
AP-1 transcription [24, 30, 31]. Cyclic AMP response
element-binding protein (CREB) can also be activated by
melanocortin receptor activation [26] resulting in improved
cell survival frommetabolic and oxidative stress [13]. For a
more comprehensive review on signaling, see previous
reviews [12, 13, 15].
MC2R AND STEROIDOGENESIS
In the classic hypothalamic-pituitary adrenal axis,
ACTH is released from the anterior pituitary gland and is
the primary systemically released endogenous melanocor-
tin peptide that binds to and activates MC2R, which is
predominantly located in the adrenal cortex, especially in
the zona glomerulosa and zona fasciculata [21]. MC2R
adrenocortical receptor signaling and subsequent release
of cortisol is a well-characterized process, which involves
MC2R signaling through cAMP and PKA to stimulate
movement of cholesterol into the mitochondria and
increases the expression of steroidogenic enzymes result-
ing in steroidogenesis [21]. Interestingly, MC2R appears to
upregulate its own expression upon stimulation by ACTH
[32] but does require an accessory protein to mobilize the
receptor to the cell surface [21].
The potent anti-inflammatory actions of glucocorti-
coids in the treatment of SLE have been studied since the
1950s [1]. In that era, it was assumed that the only clinical
benefit of ACTH was to stimulate glucocorticoid release
[33, 34]. However, subsequent research has revealed that
ACTH also binds to and activates four other melanocortin
receptor subtypes, which have biologic effects beyond
steroidogenesis. The remainder of the review will focus
on the potential therapeutic benefit of targeting these other
four melanocortin receptors, MC1R, MC3R, MC4R, and
MC5R, which provide non-steroidogenic effects of mela-
nocortin peptides.
POTENTIAL EFFECT OF MELANOCORTINS
ON IMMUNE CELLS
Melanocortin receptor signaling leads to anti-
inflammatory and immunomodulatory effects in a vari-
ety of in vitro and in vivo models (Table 1). Below, we















Fig. 1. Pro-opiomelanocortin peptide and the post-translational cleavage products [15].
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Macrophages. Melanocortin peptides have been
shown to reduce macrophage release of pro-inflammatory
mediators and increase anti-inflammatory cytokines. An
in vitro study of a mouse macrophage cell line demonstrated
that treatment with ACTH increased the anti-inflammatory
cytokine IL-10 via PKA pathway activation [29]. In addi-
tion, α-MSH significantly reduced the in vitro release of
pro-inflammatory cytokines (IL-1β, IL-8, and TNF-α) and
macrophage nitric oxide production [29]. Furthermore,
AP214, an α-MSH analogue with high affinity for MC1R,
MC3R, and MC5R, increases macrophage phagocytosis, as
detected by increases in uptake of zymosan (surface ligand
of fungi) particles and human apoptotic neutrophils by mac-
rophages. These melanocortin peptide effects on macro-
phage function might be mediated through MC3R, as
MC3R null macrophages do not demonstrate increase in
phagocytosis after AP214 treatment [76]. Regardless of the
primary melanocortin receptor or signaling pathway
affected, a decrease in inflammatory cytokine release from
macrophages could be relevant in SLE.
Nitric oxide (NO) is a very versatile component of the
immune system, with involvement in both cytotoxic and
regulatory functions. The production of reactive nitrogen
and oxygen intermediates is an important piece of the innate
immune response. The overproduction of NO has been
reported in the setting of active SLE [77]. Two studies have
demonstrated the downregulation of inducible nitric oxide
synthase (iNOS) in immune cells treated with melanocortin
peptides.α-MSH inhibits NO release in culturedmacrophage
cell lines via NF-κB-dependent and NF-κB-independent
pathways [29]. The inhibitory effects ofα-MSHonNO levels
in cultures of stimulated murine microglia, resident phagocyt-
ic cells of the CNS, were attributed to reduced iNOS
expression [52]. These results demonstrate the potent
effects of melanocortin peptides on the inflammatory
production of NO.
Table 1. Immunomodulating Effects of Melanocortins
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B Lymphocytes. B cells are an important therapeutic
target in SLE as the producer of autoantibodies. The effect
of ACTH on B cells was evaluated using the NFB/W F1
mouse model of SLE-like disease manifestations, includ-
ing proteinuria. Mice were treated with either ACTH (as
found in a highly purified gel formulation) 160 U/kg every
other day, prednisolone 5 mg/kg 6 days a week, or placebo,
for 19 weeks or until early termination (severe proteinuria
or weight gain). The ACTH group demonstrated a signif-
icant decrease in spleen weight and total spleen cell counts
compared to prednisolone (p≤0.001) and placebo (p≤
0.05). Splenic CD19+ B cells were reduced in both the
ACTH and prednisolone-treated animals compared to pla-
cebo, yet the two treatment arms affected different B cell
developmental stages. Only the ACTH-treated mice in-
creased the frequency of immature and T1 B cells.
Additionally, while the serum dsDNA autoantibody levels
increased steadily during the 19-week treatment period in
both the placebo and prednisolone, this was not observed
in the ACTH-treated mice [78]. NF-κB signaling is re-
quired for B cell differentiation and also regulates the
expression of the receptor for B cell activating factor
(BAFF or BLyS). ACTH has been previously reported to
inhibit NF-κB signaling [78]. Additionally, in a neurolog-
ical disorder, opsoclonus-myoclonus syndrome (OMS),
where BLyS concentration correlated with disease severity,
CSF BLyS levels were significantly reduced in patients
receiving conventional therapy supplemented with ACTH
(−61 %) or corticosteroids (−38 %) [79]. These data taken
together suggest a possible role for ACTH in halting the
differentiation of autoreactive B cells.
T Lymphocytes. The most extensive studies evaluating
the effects of melanocortins on T cells are done in the
contact hypersensitivity skin murine model and the exper-
imental autoimmune uveitis (EAU) murine model [44, 57,
60, 80]. In both studies, α-MSH was able to reduce the
levels of IFN-γ from T cells and also increased the regula-
tory T cell (Treg)-mediated TGF-β1 production. α-MSH-
mediated suppression of T cell IFN-γ production was
mediated through MC5R [60]. Interestingly, in the EAU
model, T cells could be driven to a Treg population by α-
MSH [60]. However, in the contact hypersensitivity model,
α-MSH was not able to induce Treg without inducing
tolerogenic dendritic cells that then drove the Treg popu-
lation [44].
Tolerogenic dendritic cells (DCs) have been described
to induce functional Tregs, and α-MSH-stimulated DCs
have been shown to express elevated levels of CD205 and
IL-10, characteristic for tolerogenic DCs. Additionally, co-
culturing α-MSH-treated DCs with CD4+ T cells yielded
an expansion of Treg cells, and these α-MSH DC-induced
Tregs reduced contact hypersensitivity upon adoptive
transfer into sensitized mice [44]. Another study looking
at a broader T cell population (CD3+) demonstrated that
treatment with an α-MSH analogue reduced the ability of
DCs to stimulate allogeneic T cells in mixed lymphocyte
reactions in vitro [47]. Lastly, in an experimental autoim-
mune uveoretinitis (EAU) mouse model, α-MSH-treated
antigen-activated T cells, in an antigen specific manner,
suppressed both the incidence and severity of EAU
through the conversion of autoantigen-reactive T cells into
Tregs [44].
CARDIOVASCULAR
Endothelial Cells. Lupus patients are at increased risk
of cardiovascular disease [81], and alterations in adhesion
molecules, anti-oxidant molecules, and serum lipids are
frequently evident. Leukocyte-endothelial cell interaction
is a process involving at least three steps: rolling, adhesion,
and transmigration into the targeted tissue. These processes
are regulated by the expression of cell adhesion molecules
(CAMs), including E-selectin, vascular CAM (VCAM)-1,
intercellular CAM (ICAM)-1, and leukocyte integrins
(Table 2).
Melanocortins have demonstrated in vitro and in vivo
effects on endothelial cells and CAMs. In human dermal
microvascular endothelial cells (HDMECs), α-MSH treat-
ment reduced the mRNA expression of E-selectin, VCAM-
1, and ICAM-1 induced by LPS or TNF-α [48]. α-MSH
impaired LPS-induced VCAM-1/ICAM-1-mediated lym-
phocyte adhesion to HDMEC monolayer [48]. Moreover,
in a mouse model of LPS-induced cutaneous vasculitis, α-
MSH suppressed vascular damage by inhibiting the sus-
tained expression of vascular E-selectin and VCAM-1
[48]. Treatment with α-MSH also improves endothelium-
dependent vasodilatation in the mouse aorta by endothelial
NO formation. α-MSH increased the expression and phos-
phorylation of endothelial NO synthase in human cultured
endothelial cells [50]. Taken together, these preclinical
research findings suggest that melanocortin peptides have
the potential to reduce vascular inflammation and damage,
potentially modulating deleterious vascular injury in
immune-mediated diseases such as SLE.
Lipids. Studies in patients with kidney disease have
demonstrated a potential beneficial effect on serum lipids
upon tetracosactide (ACTH1–24) treatment [72, 82]. Of
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note, 14 patients with idiopathic membranous nephropathy
were treated with tetracosactide for 56 days to reduce the
level of proteinuria. In addition to therapeutic effect on
proteinuria, there was a statistically significant decrease
in total serum cholesterol, triglycerides, and LDL choles-
terol; an increase in apolipoprotein B; and a corresponding
increase in HDL cholesterol and apolipoprotein A1 during
the treatment [73].
The tetracosactide effect on serum lipids does not
appear to be limited to patients with kidney disease [83].
Thirty male subjects were treated with tetracosactide, cor-
tisol, or placebo for 4 days. Statistically significant
decreases in total cholesterol, LDL cholesterol, and apoli-
poprotein B could be found in the subjects receiving tetra-
cosactide compared to subjects receiving either cortisol or
placebo. Additionally, subjects receiving tetracosactide
had statistically significant increases in apolipoprotein A1
compared to the other two groups and increased HDL
compared to placebo, but not to cortisol. Lowering of
triglyceride levels in tetracosactide-treated subjects was
observed, but the changes did not reach statistical signifi-
cance compared to the other groups. These results of
melanocortin peptides on serum lipids, while interesting,
should be viewed with caution. Tetracosactide or ACTH1–
24 is a truncated version of natural ACTH1–39, and there
are no definitive studies to suggest a similar effect between
the two peptides. Moreover, studies have not been done in
patients with SLE or even in animal models of lupus.
Therefore it is unclear whether melanocortins could have
a beneficial effect on lipid parameters in lupus patients,
although the effects with tetracosactide appear relatively
consistent between studies.
SKIN
The pathophysiology of cutaneous manifestations in
SLE occurs in several skin cell types and includes immu-
noglobulin deposition, complement-derived localized
damage, and an imbalance between keratinocyte apoptosis
and hyperproliferation [6]. α-MSH derives its name from
the first studies done demonstrating the ability of α-MSH
to increase pigmentation in melanocytes. Subsequent stud-
ies have demonstrated that MC1R is the predominant
melanocortin receptor identified in a variety of epidermal
and dermal cells, including keratinocytes, melanocytes,
Langerhans cells, sebocytes, fibroblasts, and endothelial
cells [12].
Melanocortins have demonstrated protective effects
in various in vitro skin models including ultraviolet light
Table 2. Effects of Melanocortin Peptides on Tissues and Organs
Tissue/Organ Action Reference
Skin Keratinocytes Increased proliferation
Decreased ROS following UVA exposure
[64]
[65, 66]
Fibroblasts Decreased collagen types I, III, and V
Decreased TGF-β







Dendritic cells Induce tolerogenic dendritic cells [44]
Kidney Podocytes Reduced foot process effacement [68]
Tubular epithelial cells Reduced apoptosis [14]
Kidney Reduced glomerular damage in AKI model [14]




Neurons Indirect survival [69]
Cardiovascular Endothelial cells Downregulation of ICAM-1, VCAM-1, and E-selectin
Increased eNOS expression
Increased relaxation
Increased mitochondrial superoxide dismutase
[48, 50]
Serum lipids Decreased serum triglycerides and LDL cholesterol
Increased HDL cholesterol
[72–75]
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exposure and cytokine-mediated inflammation, processes
which are implicated in SLE. The skin provides a unique
environment where all the components of the POMC sys-
tem have been identified in various cells of the epidermis
[84, 85]. The ability to induce its own melanocortin pep-
tides drives the hypothesis that the melanocortin system
has an impact in innate immune responses and epidermal
protection from UV exposure, injury, and infection.
Melanocortin receptor (MCR) activation also increased
melanocyte proliferation and reduced apoptosis [86].
Melanocortin receptor signaling decreased reactive oxygen
species production following UVA exposure of keratino-
cyte cell line in vitro [64]. MC1R agonists administered to
human fibroblasts in vitro decreased collagen type I, III,
and V production induced by TGF-β [61, 67] and in-
creased superoxide dismutase and hemoxygenase I, known
to protect against oxidative stress, in bleomycin-stimulated
fibroblasts in vitro [61]. α-MSH significantly attenuated
IL-1β-induced IL-8, a neutrophil chemokine, in dermal
fibroblasts in vitro [87]. Melanocortin receptor agonists
and α-MSH have also demonstrated anti-inflammatory
and inhibitory effects in a number of inflammatory skin
models including atopic dermatitis, psoriasis, and antigen-
induced chronic allergic skin inflammation [44, 88, 89].
KIDNEY
The pathophysiology of glomerular damage associat-
ed with SLE is based on immune complex-mediated injury
and the cellular inflammatory response to autoantibodies.
Damage can occur to mesangial tissue, endothelial tissue in
association with capillary wall destruction, or epithelial
tissue with direct cytotoxic injury to the podocyte. These
patterns of damage combine in various forms and contrib-
ute to the histological classification of SLE-associated
lupus nephritis [90]. Additionally, direct damage and de-
tachment of podocytes is a significant enough phenome-
non in the pathophysiology of lupus nephritis that its
assessment is currently being explored as a disease activity
marker in lupus nephritis [91].
Clinical research supports the potential utility of mel-
anocortin peptides as treatment for renal symptoms of SLE.
The most data in renal disorders exists for the use of
melanocortins in idiopathic membranous nephropathy
(iMN), a nephrotic syndrome not associated with SLE.
iMN is associated with immune complex formation caus-
ing subepithelial deposits, membrane thickening, and sub-
sequent inflammatory response [87], similar in pathology
to class V lupus nephritis, which is categorized as a
membranous glomerulonephritis. Tetracosactide has been
used clinically to reduce proteinuria in iMN where steroids
were demonstrated to have little clinical benefit [68, 73,
92]. In addition, tetracosactide has been shown to have
equivalency to the Ponticelli regimen of a cytotoxic agent
and steroids given in alternating months to patients with
iMN [93]. There has also been some evidence of clinical
benefit in the use of tetracosactide in patients with mesan-
gial glomerulopathies. In one case series, all six patients
with mesangioproliferative glomerulopathies and one pa-
tient with mesangiocapillary glomerulopathy, all indepen-
dent of SLE, showed improvement in proteinuria when
receiving tetracosactide [92].
The mechanism of improvement in iMN and other
renal disorders may be due to immunomodulation but
could also be due to a direct protective effect on podocytes
[87]. Preclinically, MC1R has been identified and co-
localized on podocytes in human kidney tissue [68], and
activation of these receptors leads to immunomodulatory
and renoprotective effects [94]. The renoprotective effects
were evaluated in passive Heymann nephritis model of
membranous nephropathy. ACTH, which binds all five
melanocortin receptors, including the MC2R that induces
steroidogenesis, did not significantly reduce proteinuria
[68]. However, proteinuria was significantly reduced in
this model byα-MSH, which binds all melanocortin recep-
tors except MC2R, and by the MC1R-specific agonist,
MS05. The beneficial effects of α-MSH and MS05 in
this model, and the lack of significant effect of ACTH,
suggests MC1R agonism, in the absence of MC2R ago-
nism, might protect against kidney damage, on the basis
that MC1R agonists decrease measures of oxidative stress
[68]. Treatment with an MCR agonist also protected the
morphology of the podocyte and significantly decreased
effacement and preserved glomerular architecture com-
pared [68].
Additional evidence of melanocortin-driven improve-
ment in renal outcomes was demonstrated in murine lupus
models. In one study, 80 % percent of mice treated with
placebo required early termination during the 19-week
treatment period due to development of severe proteinuria
compared to none of the ACTH-treated mice (p<0.05).
Histologic assessment demonstrated an overall reduction
in renal inflammation and glomerular structural damage,
including renal tubular dilation and degeneration, in the
ACTH-treated mice [78]. The effects of α-MSH in a sep-
arate study demonstrated similar effects on histological
preservation and decreased immunoglobulin production
[95]. This data suggests that melanocortins may attenuate
renal damage associated with lupus.
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Melanocortins have also been tested in acute kidney
injury models, where pretreatment with α-MSH ameliorat-
ed tubular injury score and serum creatinine in the cecal
ligation puncture-induced septic kidney injury model [14].
Furthermore, an exploration of the effects of melanocortins
on inflamed renal cells in vitro revealed that ACTH signif-
icantly attenuated apoptosis in renal tubular epithelial cells.
The anti-apoptotic effect was attenuated when MC1R was
transiently silenced. In addition, renal tubular epithelial
cells stimulated with TNF-α exhibit upregulated levels of
MC1R protein, suggesting that the protective effects of
melanocortin peptides are mediated by at least MC1R
[14, 96]. Further research is required to determine the
effects of melanocortin peptides in additional animal mod-
els of kidney disease and to more firmly establish the
receptors and mechanisms of action that might contribute
to any protective effects of these peptides against kidney
damage and potential preservation of renal function.
CENTRAL NERVOUS SYSTEM
CNS-associated disease in SLE patients is mainly due
to one of two pathophysiologic changes, either thrombotic
disease or generalized CNS inflammation. The CNS in-
flammatory condition is an interesting target when consid-
ering melanocortins due to the understanding of their
effects in the CNS. Melanocortin receptors are expressed
on numerous cells within the CNS, including astrocytes,
microglia, endothelial cells, and neurons [39, 69, 70]. Glial
cells are the immunocompetent cells of the CNS and, in
numerous animal models, strongly influence the pro-
inflammatorymilieu in injury, infection, and inflammation.
Melanocortins attenuated cytokine responses in glial cul-
tures when co-administered with numerous pro-
inflammatory agents. In addition, ACTH reduced apopto-
sis of oligodendroglia in mixed glial cultures stimulated
with a variety of cytotoxic agents [39, 69]. Furthermore,α-
MSH reduced NO production by decreasing the iNOS
expression in rat astrocyte cultures stimulated with LPS
and IFN-γ. This inhibitory effect of α-MSH on hypotha-
lamic cellular NO was attributed solely to an effect on
iNOS and not the endothelial NO synthase (eNOS) or
neuronal NO synthase (nNOS) [71]. Similarly, α-MSH
treatment has been shown to downregulate astrocyte
cyclooxygenase-2 (COX-2) expression and prostaglandin
E2 release [53].
The bioavailability of melanocortin peptides into the
CNS might be expected to be limited by their low level of
penetrance across the blood-brain barrier (BBB). However,
the BBBmay be more permeable in SLE, thereby allowing
increased bioavailability of circulating melanocortins into
the CNS, enabling them to attenuate pro-inflammatory
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Fig. 2. Potential mechanisms of action of melanocortin peptides in the treatment of systemic lupus erythematosus. Melanocortin peptides may reduce disease
activity through multiple potential mechanisms, including the following: systemically induced immunosuppression and anti-inflammation in disease-related
target organs and tissues secondary to ACTH-induced steroidogenesis, direct effects of MCR activation on systemically induced immunosuppression and
anti-inflammation, including regulation of B and T lymphocytes and macrophages, direct effects of MCR activation on hepatic cells to correct dyslipidemia
and possibly reduce accelerated atherosclerosis, direct immunosuppressive and anti-inflammatory effects of MCRs expressed in the epidermis and dermis on
chronic cutaneous lesions, direct protective effects of MCR activation on kidney cells particularly podocytes, and direct anti-pyretic and neuroprotective
effects of MCRs expressed in the central nervous system and central neurogenic anti-inflammation to reduce inflammation-associated neurologic and
psychiatric manifestations [94] (reprinted by permission from Macmillan Publishers Ltd).
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systemically administered melanocortins can also access
melanocortin receptor-rich areas of the intact brain, such as
the circumventricular regions, where the BBB is more
permeable [97]. In addition, binding melanocortin receptor
on peripheral nerve terminals of autonomic nerves may
provide a unique neuroimmune modulation [97].
Beyond the direct inflammatory effects of SLE in the
CNS, fever is a common constitutional symptom of SLE,
fever being a key host response to bacterial invasion aim-
ing at survival of the host [98]. Excessive fever is detri-
mental to organs, and as such, counter-regulatory processes
are in place to modulate the febrile response. This response
is thought to occur within the CNS, where febrile and
sickness responses are orchestrated [99]. Melanocortin
peptides (α-MSH and ACTH) have demonstrated anti-
pyretic effects [99–101] and are thought to contribute
significantly to these counter-regulatory systems. α-MSH
attenuated fever when administered intracerebroventricu-
larly (ICV) 30 min after systemic LPS. In addition, a MC3/
4R or a MC4R-selective antagonist (ICV) potentiated the
LPS-induced fever and reversed the anti-pyretic effect of
ICV α-MSH [98, 99]. Interestingly, though the centrally
administered MC3R and MC4R antagonist potentiated
LPS fever, it had no effect on systemic ACTH or cortico-
steroid plasma concentrations [98]. Therefore, the anti-
pyretic effects of melanocortins appear to be centrally
mediated and independent of adrenal gland stimulation,
as similar anti-pyretic effects occur in adrenalectomized
rabbits [102]. Melanocortin receptors throughout the brain
appear to be neuroprotective both against fever and
through their ability to downregulate inflammatory pro-
cesses occurring in the CNS.
CONCLUSION
Melanocortins have the potential to downregulate
inflammation in both immune cells and in cells of organs
targeted by SLE such as the skin, joints, CNS, and kidney
(see Fig. 2) [94]. A number of melanocortin agonists are in
early phase development for both their anti-inflammatory
properties and their effect on the skin [103]. Interestingly,
Acthar Gel, a highly purified preparation of the full-length
naturally occurring ACTH (1–39), has been FDA approved
for the treatment of SLE since the 1950s and has demon-
strated good clinical efficacy in historic literature [33, 34].
The ability to target an endogenous system, which is
designed for both modulation of inflammatory processes
and organ protection, makes the melanocortin system an
ideal receptor target for further development.
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